Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia

Michael J. Keating(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Maher Albitar(Genomic Health (United States)), Alice Lynn(The University of Texas MD Anderson Cancer Center), Susan Lerner(Molecular Templates (United States)), William Plunkett(The University of Texas MD Anderson Cancer Center), Deborah A. Thomas(Washington University in St. Louis), Francis J. Giles(National University of Ireland), Michelle A. Detry(Berry & Associates (United States)), Michael Andreeff(The University of Texas MD Anderson Cancer Center), Susan O’Brien(University of California, Irvine), Charles Koller(The University of Texas MD Anderson Cancer Center), Jörge E. Cortes(Augusta University Health), William G. Wierda(The University of Texas MD Anderson Cancer Center), Stefan Faderl(The University of Texas MD Anderson Cancer Center)
Journal of Clinical Oncology
March 15, 2005
10.1200/jco.2005.12.051
Cited by 951

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
|Blood|2017|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k